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ARTICLE OPEN ACCESS
Dimethyl fumarate suppresses granulocyte
macrophage colony-stimulating
factor–producing Th1 cells in CNS
neuroinflammation
Farinaz Safavi, MD, PhD, Rodolfo Thome, PhD, Zichen Li, MSc, Guang-Xian Zhang, MD, PhD, and
Abdolmohamad Rostami, MD, PhD






To study the immunomodulatory effect of dimethyl fumarate (DF) on granulocyte macro-
phage colony-stimulating factor (GM-CSF) production in CD4+ T cells in experimental au-
toimmune encephalomyelitis (EAE) and human peripheral blood mononuclear cells
(PBMCs).
Methods
We collected splenocytes and CD4+ T cells from C57BL/6 wild-type and interferon (IFN)-
γ–deficient mice. For human PBMCs, venous blood was collected from healthy donors, and
PBMCs were collected using the Percoll gradient method. Cells were cultured with anti-CD3/
28 in the presence/absence of DF for 3 to 5 days. Cells were stained and analyzed by flow
cytometry. Cytokines were measured by ELISA in cell supernatants. For in vivo experiments,
EAE was induced by myelin oligodendrocyte glycoprotein35–55 and mice were treated with oral
DF or vehicle daily.
Results
DF acts directly on CD4+ T cells and suppresses GM-CSF–producing Th1 not Th17 or single
GM-CSF+ T cells in EAE. In addition, GM-CSF suppression depends on the IFN-γ pathway.
We also show that DF specifically suppresses Th1 and GM-CSF–producing Th1 cells in
PBMCs from healthy donors.
Conclusions
We suggest that DF exclusively suppresses GM-CSF–producing Th1 cells in both animal and
human CD4+ T cells through an IFN-γ–dependent pathway. These findings indicate that DF
has a better therapeutic effect on patients with Th1-dominant immunophenotype. However,
future longitudinal study to validate this finding in MS is needed.
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MS, the leading cause of disability in young adults, is an in-
flammatory demyelinating disease with axonal injury in the
CNS.1 The rapidly growing number of diagnosed cases and
available immune-modifying therapies in recent years is mo-
tivating scientists and clinicians to further study the mecha-
nism of action of currently approved medications to discover
novel underlying pathways that can be targeted to develop
new and more efficient treatments for MS.
Patients with relapsing-remitting MS (RRMS) patients are trea-
ted with oral dimethyl fumarate (DF) since 2013 in the United
States,2 and DF is added to the armamentarium of disease-
modifying therapies for MS. In terms of an underlying mecha-
nism of action, DF inhibits interleukin (IL)-12p35 and IL-23p19
transcription in dendritic cells. This leads to the generation of
type-2 dendritic cells, which indirectly increases IL-4+ Th2 cells in
both experimental autoimmune encephalomyelitis (EAE) and
human cells and ameliorates inflammatory responses.3,4 In ad-
dition, EAEmice treated with DF show a significant reduction in
the total number of interferon (IFN)-γ–, IL-17–, and granulocyte
macrophage colony-stimulating factor (GM-CSF)–producing
CD4+ T cells among CNS-infiltrating cells.5 These findings add
to the role of DF in decreasing the inflammatory profile of T cells
indirectly by changing the phenotype of antigen presenting cells,
but the direct effect of DF on pathogenic T-cell subtypes has not
been adequately studied.
Among the various types of immune cells involved in the
pathogenesis of EAE, T cells have been the main focus of
research because of their pathogenic role in animal models of
demyelination and the abundance of T cells in active de-
myelinating brain lesions in patients with MS.6,7
Th1 and Th17 cells are considered the main culprits in EAE
pathogenicity,8,9 and their signature cytokines, IFN-γ and IL-17,
play a role in disease pathogenesis.10,11 Lack of IFN-γ leads tomore
severe EAE, and the absence of IL-17 does not affect EAE
development.12,13 Given that neither Th1 (IFN-γ) nor Th17 (IL-
17) signature cytokines are required for the development of EAE,14
we and others have shown that GM-CSF is an essential cytokine
for EAE induction. GM-CSF–producing CD4+ T cells can effec-
tively induce EAE by passive transfer, and lack of GM-CSF in Th1
or Th17 cells abrogates their encephalitogenicity. In addition, GM-
CSF–deficient mice are resistant to EAE induction.15,16
Here, we studied the direct effect of DF on CD4+ T cells and
their cytokine profiles. We demonstrate that DF significantly
decreases GM-CSF in CD4+ T cells in vitro and in vivo.
Further evaluation showed that the decrease in GM-CSF is
more prominent in Th1 than that in Th17 or single GM-
CSF+CD4+ T cells. In addition, the suppressive effect of DF
on GM-CSF was abrogated by the lack of IFN-γ. We also
evaluated the effect of DF on human PBMCs and confirmed
that DF significantly decreases GM-CSF in Th1 cells.
Methods
Mice
Female C57BL/6 mice, 7–9 weeks old, were obtained from
Jackson Laboratory (Bar Harbor, ME). Mice were housed at
animal facility at Thomas Jefferson University with water and
food ad libitum. All experimental procedures were approved
by the Institutional Animal Care and Use Committee.
EAE induction and clinical evaluation
Mice were immunized subcutaneously with 200 μg of myelin
oligodendrocyte glycoprotein (MOG)35–55 (GenScript, Piscat-
away, NJ) emulsified in complete Freund’s adjuvant (DIFCO
Laboratories) containing Mycobacterium tuberculosis H37Ra (5
mg/mL; DIFCO Laboratories, Detroit, MI). In addition, mice
were intraperitoneally injected with 200 ng of pertussis toxin at
0 and 48 hours after immunization. Clinical EAE was assessed
daily in a blind fashion using the clinical scoring system from 0:
normal to 5: death as described previously.17
DF treatment
DF (Sigma-Aldrich, St. Louis, MO) was used in an emulsion of
0.8% methylcellulose. For in vivo treatment, DF solution was ad-
ministered by oral gavage twice daily (750 μg for 25 g mice in 200
μL volume), starting the day of EAE induction until termination
(day 23 post immunization). The solution was prepared early
everyday and stored at 4°C. Mice receiving vehicle were used as
controls.
Isolation of CNS-infiltrating mononuclear cells
and splenocytes
To collect mononuclear cells (MNCs), mice were extensively
perfused at day 23 post immunization with ice-cold phosphate
buffered saline. For spleen cells, spleens were collected and dis-
rupted in 70 μm cell strainer before RBC lysis. To collect CNS-
infiltrating cells, brains and spinal cords were removed, thinly
minced in Liberase TL (Roche, Indianapolis, IN), and incubated
at 37°C for 30 minutes. Then, the CNS was strained through
a 70 μm cell strainer, andMNCs were enriched by centrifugation
on a 70/30 Percoll gradient for 30 minutes at 2,000 rpm.17
Splenocyte and lymphocyte culture and
ELISA experiments
Spleen cells were cultured in Iscove Modified Dulbecco medium
(Gibco, Gaithersburg, MD) supplemented with 10% fetal bovine
Glossary
DF = dimethyl fumarate; EAE = experimental autoimmune encephalomyelitis; GM-CSF = granulocyte macrophage colony-
stimulating factor; MNC = mononuclear cell; RRMS = relapsing-remitting MS; WT = wild type.
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serum (Gibco), 5% L-glutamine (Gibco), 5% penicillin/
streptomycin (Gibco), and β-mercaptoethanol (Sigma). Spleen
cells were stimulated with 1 μg/mL anti-CD3/CD28 agonistic
antibodies for 72 hours at 37°C, 5% CO2. For antigen-specific
recall response, CNS-infiltrating cells from EAE mice, at a con-
centration of 1 × 106 cells/mL, were stimulated with 10 μg/mL
MOG35–55 at 37°C, 5% CO2. At the indicated time points,
supernatants were collected and centrifuged to eliminate cellular
debris. Cytokine levels in supernatants were measured by ELISA.
We analyzed the following cytokines: GM-CSF (R&D Systems,
Minneapolis, MN, DY415), human GM-CSF (R&D Systems
DY215), IFN-γ (R&D Systems DY485), human IFN-γ (R&D
Systems DY285), IL-17 (R&D Systems DY421), and human IL-
17 (R&D Systems DY317).
Purification of CD4+ T cells
MNCs from spleens were subjected to positive selection
according to the manufacturer’s recommendation (CD4
microbeads; Miltenyi Biotec, Auburn, CA, 130-049-201).
Proliferation assay
Splenocytes were cultured in 96-well plates at a concentration
of 1 × 106 cells/mL and stimulated with anti-CD3/28 (1 μg/
mL each) for 48 hours. Cells were pulsed with 0.5 μCi of 3H-
thymidine for the last 18 hours. Thymidine incorporation was
measured using a scintillation counter.
Human blood samples and cell culture
All subjects provided informed consent before their participa-
tion in the current study. All human studies were approved by
the Thomas Jefferson University Institutional Review Board.
Blood was obtained from 8 healthy donors at the Department
of Neurology, Thomas Jefferson University. PBMCs were
collected by Ficoll-Paque Plus density gradient centrifugation.
PBMCs were washed and cultured at a density of 1 × 106 cells/
mL in X-VIVO 15 serum-free medium. Cells were stimulated
with 1 μg/mL of anti-CD3 (HIT3a; BD Biosciences, San Jose,
CA) and 1 μg/mL anti-CD28 (CD28.2; BD Biosciences) for
120 hours in the presence of 0.1 μg/mLof DF (Sigma-Aldrich).
Flow cytometry experiments
For analysis of surface markers, MNCs were surface stained in
flow cytometry (FACS) buffer (phosphate buffered saline
containing 3% fetal bovine serum and 0.02% NaN3) with
fluorescence antibodies for 20 minutes at 4°C. For analysis of
cytokine production, MNCs were activated with phorbol 12-
myristate 13-acetate (50 ng/mL), ionomycin (500 ng/mL),
andGolgi-Stop (1 μg/mL) for 4 hours. Then, cells were surface
stained as mentioned previously, before being fixed and per-
meabilized with buffers (Fix/Perm; ThermoFisher, Frederick,
MD). Finally, cells were incubated with cytokine-specific
antibodies for 30 minutes at 4°C. All antibodies and reagents
used in this section were purchased from BD Biosciences, ex-
cept for phorbol 12-myristate 13-acetate and ionomycin (both
from Sigma-Aldrich). Samples were acquired on an FACS Aria
equipment (BD Biosciences). Analyses were performed with
FlowJo software (Tree Star, Ashland, OR).
Statistical analysis
Data are presented as mean ± standard error of the mean.
Statistical analysis was performed using one-way analysis of
variance or the Kruskal-Wallis test (all analyses performed with
GraphPad Prism software, San Diego, CA). A probability level
(p value) of *: p < 0.05, **: p < 0.01, and ***: p < 0.001 was
statistically significant for all tests. All error bars represent
standard error of the mean. For human results, we used pre-
treatment and posttreatment paired t test analysis.
Data availability
Raw FACS and ELISA files are not included in this article. Any
unpublished and anonymized data will be shared upon re-
quest from a qualified investigator.
Results
DF acts directly on CD4+ T cells and decreases
GM-CSF production
To evaluate the role ofDF onGM-CSF production inT cells, we
first collected splenocytes from B6 wild-type (WT) mice and
cultured them with anti-CD3/CD28 in the presence
and absence of DF (1 μg/mL) for 72 hours. We found that GM-
CSF in culture supernatants was significantly lower in
DF-treated cells compared with controls (figure 1A). FACS
analysis of the same cells showed a significant reduction of GM-
CSF in both CD4+ and CD8+ T cells (figure 1B). As previously
shown in several studies, DF induces T-cell lymphopenia in
patients with MS.18 To confirm that the effect of DF on the
T-cell cytokine profile is not dependent on its lymphopenic
effect, we performed a proliferation assay on activated spleno-
cytes with anti-CD3/CD28 in the presence or absence of varying
doses of DF. Administration of DF at a dose of 1 μg/mL, which
we used in all our in vitro experiments, did not show a significant
suppressive effect on splenocyte proliferation (figure 1C).
Following the above-mentioned experiment, we studied howDF
directly affects purified CD4+ T cells from mice. CD4+ T cells
were isolated and cultured with anti-CD3/CD28 Abs with or
withoutDF for 72 hours.Wemeasured IFN-γ, GM-CSF, and IL-
17 in the supernatant after the incubation period. We found that
DF significantly decreased GM-CSF and IFN-γ, but not IL-17, in
purified CD4+ T cells compared with controls (figure 1D). In
addition, FACS analysis of the same cells demonstrated that DF
decreased GM-CSF in IFN-γ+CD4+ T (Th1) cells (figure 1E).
DF treatment significantly decreased GM-CSF+
Th1 cells in CNS-infiltrating cells
To analyze the immunomodulatory effect of DF treatment in
EAE, we first immunized all mice and then treated half of them
with oral DF in an emulsion of 0.8% methylcellulose (DF
group) and the other half with a similar volume of 0.8%
methylcellulose vehicle (control group). Mice in the control
group developed EAE, with an average severity of around 2.5 in
scoring (score range from 1.25 to 4 with a median score of
2.625). By contrast, DF-treated mice showed very mild clinical
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Figure 1 DF decreases GM-CSF production and GM-CSF+Th1 cells in mouse splenocytes
Splenocytes fromwild-type (WT) mice were stimulated with 1 μg/mL of anti-CD3/28 antibody in the presence or absence of DF (1 μg/mL) for 72 hours. (A) GM-
CSF levels in culture supernatantswere determined by ELISA. Data are representative of 3 experiments (mean ± SEM; n = 4 replicates per group). (B) Cells were
stimulatedwith ionomycin/PMA andGolgiPlug in the last 4 hours of culture. After intracellular staining for GM-CSF, flow cytometry analysis of gated CD4+ and
CD8+ T cells showed that DF administration decreased GM-CSF production in both CD4+ and CD8+ T cells. (C) Proliferation assay on splenocytes treated with
different DF doses. DF did not affect proliferation of splenocytes at a dosage of 1 μg/mL. (D) CD4+ T cells were purified fromWT spleen cells and stimulated
with anti-CD3/28 in the presence or absence of DF. IL-17, IFN-γ, and GM-CSF weremeasured in cell supernatants. DF decreased IFN-γ and GM-CSF, but not IL-
17. (E) Flow cytometry analysis demonstrated that DF significantly reduced GM-CSF production in IFN-γ–producing CD4+ (Th1) cells. DF = dimethyl fumarate;
GM-CSF = granulocytemacrophage colony-stimulating factor; IFN = interferon; IL = interleukin; PMA = phorbol 12-myristate 13-acetate; SEM = standard error
of the mean. ***p < 0.001.
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signs with an average clinical score of ≤1 (score range from 0 to
1.5 with a median score of 0.75) (figure 2A).
We killed the mice at disease peak (day 23) and assessed the
number of infiltratingMNCs in the CNS of both DF-treated and
control groups. In addition to counting the total number of in-
filtrating cells, we evaluated the immunophenotype of those cells
by flow cytometry. The total number of CD4+ T cells and GM-
CSF+CD4+ T cells was dramatically decreased in the CNS of the
DF-treated group (figure 2B).We also looked at IFN-γ and IL-17
inCNS-infiltratingCD4+T cells and, interestingly, found thatDF
decreases GM-CSF+CD4+ cells that coproduce IFN-γ, but not
IL-17 (figure 2C), given that DF has a greater suppressive effect
in vivo onGM-CSF–producingTh1 cells than that onTh17 cells.
Splenocytes from treated and control mice were isolated, cultured,
and stimulatedwithMOG33–35 for 72hours.GM-CSF, IFN-γ, and
IL-17 were measured in culture supernatants by ELISA. As shown
in figure 2D, splenocytes from DF-treated mice produced a sig-
nificantly decreased amount ofGM-CSFand IFN-γ, but not IL-17.
DF requires an intact IFN-γ pathway to
suppress GM-CSF in CD4+ T cells
Based on the observation that DF suppresses GM-CSF pre-
dominantly in Th1 cells, and to further evaluate the underlying
mechanism of the suppressive effect of DF on GM-CSF, we
investigated whether IFN-γ plays a role in this phenomenon.
WT and IFN-γ–deficient splenocytes were cultured and stim-
ulated with anti-CD3/28 in the presence or absence of DF.
Although DF suppressed GM-CSF–producing CD4+ T cells
and GM-CSF cytokines in the supernatant of WT splenocytes,
the lack of IFN-γ abrogated the effect of DF on GM-CSF in
CD4+T cells. This finding implies that IFN-γ plays a crucial role
in the suppressive effect of DF on GM-CSF (figure 3, A and B).
DF decreases Th1 and GM-CSF–producing Th1
cells in human PBMCs
To determine the best dosage of DF in human in vitro experi-
ments, we performed a proliferation assay and treated cells with
10, 1, and 0.1 μg/mL of DF as described previously. Based on
our result, 0.1 μg/mL DF had the least toxic effects on human
PBMCs (data not shown). To evaluate the effect of DF on
human PBMCs, we cultured and stimulated PBMCs from
healthy donors with human anti-CD3/28 with or without DF
(0.1 μg/mL) for 120 hours. Cells were analyzed with flow
cytometry after 5 days, andmultiple cytokines weremeasured by
ELISA in cell supernatants. For statistical analysis, we used the
paired t test to compare pretreatment and posttreatment results.
DF treatment significantly reduced IFN-γ+CD4+ (Th1) T cells,
and ELISA analysis of PBMC culture supernatants demon-
strated that DF significantly decreased IFN-γ production (figure
3C). In terms of GM-CSF–producing CD4+ T cells, DF sig-
nificantly decreased GM-CSF+ Th1 cells with no effect on total
GM-CSF–producing CD4+ T cells, implying that the suppres-
sive effect of DF onGM-CSF is mostly on Th1 cells (figure 3D).
Discussion
DF was approved by the Food and Drug Administration for the
treatment of MS in 2013, and its efficacy has been well demon-
strated. During 2 years of treatment, DF reduced clinical relapse
and lesion frequency while improving health-related quality of life
in adults with RRMS.19,20 However, the underlying therapeutic
mechanism of DF is still under investigation. DF has neuro-
protective effects,4,21,22 including reducing spinal cord in-
flammation and protecting myelin and neurons.4,23 Also,
researchers who have studied the Nrf2 transcriptional pathway
and oxidative stress that DF modulates4,21,24 found that both DF
and its active metabolite, monomethyl fumarate, induce the re-
active oxygen species scavenger glutathione in oligodendrocytes,
astrocytes, and hippocampal cells.22,25,26Other pathways have also
been reported, including the hydroxycarboxylic acid receptor 2
pathway and nuclear factor kappa-light-chain-enhancer of acti-
vated B cells.23,27,28 DF has been shown to promote Th2 cytokine
profiles,3,22,29 and transferring DF-induced IL‐17AlowIFN‐γlowIL‐
4+CD4+ T cells has demonstrated its therapeutic effect in EAE.30
In patients with RRMS after 6 months of DF treatment, the
proportion of Th2 cells was increased amongmemory T cells but
with a decrease in the proportion of Th1 and with no change in
Th17 cell proportion among memory T cells.31 Another study,
however, showed a decrease in CD4+ T cells producing IFN-γ,
IL-17, andGM-CSF, with no significant change in IL-10 and IL-4
after 12months.32We also found that direct administration ofDF
decreased proinflammatory cytokine production in the super-
natant of human PBMCs obtained from healthy subjects. When
we took a closer look at CD4+T-cell subsets, DF suppressed only
GM-CSF+Th1 cells, but not GM-CSF+Th17 or GM-CSFonly
CD4+ T cells. One limitation of our study is that the human data
are based on very small number of samples from healthy donors.
Further studies are necessary to confirm the effect of DF onGM-
CSF–producing cells from patients with MS.
Although IL-17 and IFN-γ are implicated in MS, mice still
develop EAE even in the absence of these cytokines.33,34 Pre-
vious studies have shown that GM-CSF secreted by CNS-
infiltrating T helper cells is essential for EAE, evenmore so than
IL-17 or IFN-γ. Lack of GM-CSF or GM-CSF receptor
abrogates EAE development, and adoptively transferred GM-
CSF–deficient Th1 or Th17 cells do not induce EAE.15 We
showed that DF caused a decrease in GM-CSF+ Th1 cells in
both the periphery and CNS-infiltrating cells during EAE, and
given the fact that GM-CSF–expressing cells are the crucial
determinant of EAE susceptibility and progression, one of the
underlying therapeutic mechanisms of DF appears to be
through suppression of GM-CSF+ Th1 cells.
In a variety of T helper cell populations, different transcription
factors, including bhlhe40, RORγt, T-bet, GATA-3, and
STAT5,35–38 are active at multiple time points. It has been
reported that IL-7–activated STAT5 promotes GM-CSF gen-
eration of CD4+ T cells, which differ from RORγt-, T-bet–, and
GATA-3–promotedGM-CSF–producing CD4+ T cells (Sheng
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Figure 2DF ameliorates experimental autoimmune encephalomyelitis and suppresses GM-CSF–producing Th1 cells in the
CNS
(A)Wild-typeB6micewere immunizedwith 200μg ofMOG35–55 andwere treatedwithDF (treatment group) or placebo (control group) by oral administration starting
on the day of immunization. Clinical signs were scored daily following a 0–5 scale. Data represent 1 of 3 experiments and themean clinical scores ± SEM (n = 5 each
group). (B) CNS-infiltrating cells fromDF-treated and controlmice were isolated on day 23 of disease. DF treatment significantly decreased total CD4+ T cells and GM-
CSF–producing CD4+ T cells among CNS-infiltrating cells. (C) Cells were stained with GM-CSF, IFN-γ, and IL-17A antibodies and analyzed by flow cytometry. We found
that GM-CSF was decreased in Th1 cells, but not Th17 cells, after DF treatment. (D) Splenocytes from both treated and control groups were collected and cultured/
stimulated with 25 μg/mL MOG35–55 for 72 hours. Concentrations of GM-CSF, IFN-γ, and IL-17A in culture supernatants were measured by ELISA. There was
significantly lessGM-CSFand IFN-γ in treatedmice comparedwith controls. **p<0.01; and***p<0.001.Oneof 2 experiments is shown.DF= dimethyl fumarate;GM-
CSF = granulocyte macrophage colony-stimulating factor; IL = interleukin; MOG = myelin oligodendrocyte glycoprotein; SEM = standard error of the mean.
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Figure 3 The suppressive effect of DF on GM-CSF depends on IFN-γ in murine cells
(A)Splenocyteswere isolated fromwild-type (WT)and IFN-γ−/−mouseandstimulatedwith1μg/mLofanti-CD3/28antibodies in thepresenceorabsenceofDF (1μg/mL) for72
hours.DF treatment significantly decreasedGM-CSF inCD4+T cells fromWTbutnotCD4+T cells from IFN-γ−/−mice. (B)MeasurementofGM-CSF in cell supernatantsbyELISA
confirmed the same finding.Dataaremean±SEMandrepresentativeof1of 3experiments.DF reducedGM-CSFproductionandGM-CSF+Th1cells inhumanPBMCs. PBMCs
fromhealthydonors (n= 8)werestimulatedwith1μg/mLofanti-CD3/anti-CD28antibody in thepresenceorabsenceofDF (0.1μg/mL) for120hours. (C)Cellswerestimulated
withPMA/ionomycinandGolgiPlug in the last4hoursofculture. Flowcytometryanalysis showedthatDFtreatmentdecreased IFN-γ+CD4+ (Th1)cells.Measurementof IFN-γ in
cell supernatants confirmed that DF reduced IFN-γ in human PBMC culture. (D) DF treatment did not affect the total percentage of GMCSF+CD4+ T cells but significantly
decreasedGM-CSF–producingTh1cells.Apaired t testwasusedforthestatisticalanalysisofhumanPBMCresultsbeforeandafter treatment.DF= dimethyl fumarate;GM-CSF
= granulocyte macrophage colony-stimulating factor; PMA = phorbol 12-myristate 13-acetate; SEM = standard error of the mean. *p < 0.05; **p < 0.01, and ***p < 0.001.
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et al., 2014). Assay for transposase-accessible chromatin using
sequencing analysis of GM-CSF–expressing cells showed an
open IFN-γ locus in both GM-CSF– and ex-GM-CSF–
expressing cells, and single-cell RNA-sequencing showed that
pathogenic Th17 cells gain Th1-like characteristics once they
enter the mouse-inflamed CNS.34,39 On the epigenetic basis,
GM-CSF–producing T cells are also more related to IFN-γ+
T cells. Here, we show that DF affects only GM-CSF+IFN-
γ+CD4+ T cells, and its GM-CSF suppressive effect relies on an
intact IFN-γ pathway. Determining whether DF affects one or
several transcription factors in this pathogenic T-cell subset
could provide insights into its precise therapeutic mechanisms
in MS. Future research on DF should focus on the molecular
pathway of GM-CSF and IFN-γ generation after DF treatment.
In conclusion, we evaluated the role of DF on CD4+ T cells and
its effects on GM-CSF production. For mouse splenocyte
experiments, GM-CSF–producing Th1 T cells were reduced, but
other GM-CSF–producing T cells were not. For EAE model
experiments, DF decreased the percentage of GM-CSF+ Th1
cells in the CNS. In human ex vivo experiments, GM-CSF+ Th1
cells were reduced in healthy donor PBMCs after DF treatment;
however, a larger study in patients before and after DF treatment
is needed to validate current findings in MS. We also demon-
strated that the suppressive effect of GM-CSF is through the IFN-
γ pathway. The molecular basis of the effects of DF on GM-
CSF–producing T cells is unknown and merits further study.
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